Full-Time

Ancillary Sourcing Specialist

Posted on 11/22/2025

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

Compensation Overview

$74k - $105.8k/yr

Remote in USA

Remote

Category
People & HR (1)
Required Skills
Market Research
Supply Chain Management
Risk Management
Data Analysis
Requirements
  • Bachelor's or master's degree in business administration, supply chain management, life sciences, or a related field
  • 3+ years of experience in strategic sourcing or procurement roles
  • Strong understanding of clinical trials sourcing processes and regulations
Responsibilities
  • Address incoming client inquiries for ancillary supplies promptly, providing clear and accurate information on pricing, product availability, lead times, and other relevant details
  • Analyze client requirements and project specifications to create customized proposals that meet client needs effectively
  • Join commercial meetings with customers to engage and approach target clients
  • Collaborate with internal teams and external vendors to gather necessary information for accurate client quotations while ensuring compliance with pricing guidelines and regulations
  • Review and refine pricing strategies to remain competitive in the marketplace while maximizing company profitability
  • Track project progress, monitor timelines, and address any issues/risks that may impact deliverables
  • Request procurement-related documentation as required
  • Maintain up-to-date customer messaging at all times
  • Ensure all billing activities are forecasted within the month
  • Conduct detailed market analysis to identify emerging trends, potential growth opportunities, and competitive dynamics in the ancillary supplies market
  • Collaborate with the Vendor Management team to develop sourcing strategies for ancillary materials, services, and suppliers based on project requirements and organizational goals
  • Conduct market research to identify potential suppliers that meet quality standards, cost-effectiveness requirements, timelines, and regulatory compliance
  • Contribute to building and maintaining relationships with key suppliers/vendors involved in ancillary sourcing activities for clinical trials
  • Assist in negotiations with suppliers/vendors to secure service level agreements (SLAs) and other operational and quality terms while ensuring regulatory compliance for clinical trials
  • Monitor supplier performance against established metrics/SLAs to maintain compliance with quality standards, delivery timelines, and cost targets within drug sourcing projects for clinical trials
  • Support data analysis related to sourcing performance, costs, savings achieved, and other key metrics; contribute insights for decision-making
  • Provide regular reports highlighting trends and recommendations for process optimization within ancillary sourcing projects for clinical trials
  • Ensure all purchase orders are tracked with relevant information to capture and monitor key data
  • Collaborate closely with cross-functional teams including Operations personnel (clinical operations teams), Quality Assurance/Quality Control (QA) teams, Qualified Persons (QPs), and Supply Chain teams to ensure seamless integration of clinical trial supplies/services into ongoing operations
  • Liaise with internal stakeholders (e.g., Clinical Operations) to understand project needs, timelines, specifications, and budget constraints; align sourcing strategies accordingly
  • Communicate effectively with Operations to ensure a smooth transition from quote/purchase order to delivery, including timelines
  • Identify potential risks associated with ancillary sourcing activities (e.g., supply chain disruptions) and contribute to developing risk mitigation strategies/crisis management plans to minimize impact on clinical trial operations
  • Ensure compliance with relevant regulations/guidelines, including GxP, throughout all stages of procurement/sourcing activities specific to clinical trials
  • Identify opportunities for process improvements within the ancillary sourcing function and propose changes to optimize efficiency and effectiveness through automation or digitization where applicable
  • Support the QA team in investigating customer complaints, deviations, or audits related to ancillaries sourced for clinical trials
  • Provide necessary information, documentation, and support to assist in determining root causes, implementing corrective actions, and preventing future occurrences
Desired Qualifications
  • Experience in ancillary sourcing activities
  • Knowledge of Global markets and ancillary sourcing
  • Clinical Trial supply experience
  • Familiarity with clinical trial protocols and regulations governing ancillary sourcing
  • Understanding of indirect sourcing processes and best practices within the pharmaceutical industry
  • Experience in Proposal Development / Key Account Management with good customer service skills
  • Proficiency in supplier evaluation, negotiation support, and contract management
  • Strong organizational and coordination skills
  • Strong communication and interpersonal skills

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Simplify Jobs

Simplify's Take

What believers are saying

  • OneOncology $5B acquisition completed December 2025 boosts specialty oncology leadership.
  • EyeSouth retina business $1.1B deal expands Retina Consultants, accretive to EPS post-closure.
  • FY2026 EPS guidance raised to $17.65–$17.90 despite revenue headwinds from biosimilars.

What critics are saying

  • Frank R. Cruz investigation triggers shareholder lawsuits after May 6, 2026 Q2 revenue miss.
  • McKesson and Cardinal Health seize specialty drug share via aggressive GLP-1 pricing.
  • Inflation Reduction Act price cuts compress margins beyond $2B Q2 2026 headwind.

What makes Cencora unique

  • Cencora rebranded from AmerisourceBergen in August 2023, trading as COR on NYSE.
  • Cencora operates 1,400 locations across 50+ countries for global pharmaceutical distribution.
  • Cencora uniquely serves human and animal health with specialty pharmacy and MSO platforms.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Mar 23rd, 2026
Cencora buys EyeSouth Partners' retina business for $1.1B to expand Retina Consultants of America

Cencora has signed a definitive agreement to acquire EyeSouth Partners' retina business for $1.1 billion. The affiliated retina physicians will join Cencora's Retina Consultants of America, a leading management services organisation. The pharmaceutical solutions company expects the acquisition to be slightly accretive to its adjusted diluted earnings per share in the first twelve months following closure, net of financing costs. The transaction requires regulatory approvals and customary closing conditions. Cencora's reaffirmed fiscal 2026 financial guidance does not currently include the transaction closing within that fiscal year. BofA Securities served as lead financial advisor to Cencora, whilst Jefferies advised EyeSouth Partners, a portfolio company of Olympus Partners.

The Associated Press
Mar 17th, 2026
Cencora CFO James Cleary to retire after eight years, search underway for successor

Cencora has announced that Chief Financial Officer James F. Cleary will retire effective 30 June 2026. The pharmaceutical solutions company has engaged an executive search firm to identify potential successors from internal and external candidates. Cleary, 62, has served as CFO since November 2018 and joined Cencora in February 2015 following its acquisition of MWI Veterinary Supply, where he had been chief executive officer for over a decade. He will serve in an advisory capacity through the end of 2026 to ensure a smooth transition. Cencora reaffirmed its previously issued adjusted diluted earnings per share guidance range of $17.45 to $17.75 for fiscal year 2026. The company, ranked number 10 on the Fortune 500, generates more than $300 billion in annual revenue.

TradingView
Feb 11th, 2026
Cencora prices $3B senior notes offering across multiple maturities

Cencora has priced a $3 billion senior notes offering across various maturities, the company announced on 10 February 2026. No further details about the specific maturities, interest rates or intended use of proceeds were disclosed in the announcement.

Yahoo Finance
Feb 4th, 2026
Cencora raises fiscal 2026 guidance after completing OneOncology acquisition

Cencora reported 12% adjusted operating income growth and 9% adjusted diluted EPS growth in its fiscal 2026 first quarter, driven by its US healthcare solutions business. The company raised its full-year guidance to reflect year-over-year adjusted operating income growth of 11.5% to 13.5%. CEO Robert Mauch announced the completion of Cencora's acquisition of the majority remaining equity interest in OneOncology. The deal strengthens Cencora's specialty pharmaceutical leadership and MSO (management services organisation) platform. Cencora's strategy focuses on three priorities: strengthening leadership in specialty pharmaceuticals, partnering with market leaders, and enhancing patient access to pharmaceuticals. The company is leveraging technology and advanced analytics to improve customer experience and operational excellence whilst expanding its pharmaceutical-centric MSO footprint.

Yahoo Finance
Feb 4th, 2026
Cencora beats profit estimates on specialty drug demand, completes $5B OneOncology acquisition

Cencora beat Wall Street's first-quarter profit estimates on Wednesday, driven by sustained demand for specialty medicines and GLP-1 therapies. The drug distributor reported adjusted earnings of $4.08 per share, exceeding analysts' expectations of $4.04. The company completed its $5 billion acquisition of OneOncology from TPG in December, strengthening its presence in cancer care. It raised its fiscal 2026 adjusted operating income growth forecast to 11.5% to 13.5%, up from 8% to 10% previously. However, quarterly revenue of $85.93 billion fell short of expectations of $86.03 billion, sending shares down 5% in pre-market trading. Sales at its largest unit, US healthcare solutions, rose 5% year-over-year to $76.2 billion, boosted by prescription volumes of weight-loss drugs and specialty medicines.

INACTIVE